Coeptis Therapeutics Announces Research Demonstrating The Potential Of SNAP-CAR T-cells To Reduce Tumor Burden And Growth In HER2 And CD20 Expressing Cancers Will Be Presented At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, will be presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). The research suggests that SNAP-CAR can potentially enable the development of T-cell therapies that can be tuned by adaptor dose and targeted toward multiple antigens, potentially avoiding toxicities and relapse due to antigen loss.
October 31, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coeptis Therapeutics' research on the SNAP-CAR T-cell platform could potentially enable the development of T-cell therapies that can be tuned by adaptor dose and targeted toward multiple antigens. This could have a positive impact on the company's stock in the short term.
The announcement of the research presentation at a prestigious conference like SITC 2023 could generate positive sentiment among investors. The potential of the SNAP-CAR T-cell platform to target multiple antigens and avoid toxicities and relapse due to antigen loss could be seen as a significant advancement in the field of cancer treatment, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100